This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
by Zacks Equity Research
Seattle Genetics' (SGEN) Adcetris gets Breakthrough Therapy designation by the FDA for the frontline treatment of certain lymphoma subtypes.
Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark
by Zacks Equity Research
Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.
Seattle Genetics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Seattle Genetics has been struggling lately, but the selling pressure may be coming to an end soon.
Seattle Genetics (SGEN) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit
by Zacks Equity Research
Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.
Spectrum (SPPI) Earnings and Sales Miss Estimates in Q2
by Zacks Equity Research
Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.
Endo (ENDP) Beats on Q2 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Endo International (ENDP) gains on better-than-expected Q2 results on the back of growth in demand for Xiaflex and momentum in its Sterile Injectables business.
Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.
Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y
by Zacks Equity Research
Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.
Perrigo (PRGO) Beats on Q2 Earnings, Cuts View, Shares Down
by Zacks Equity Research
Perrigo (PRGO) reports mixed second-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018.
Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales
by Zacks Equity Research
Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.
Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise
by Zacks Equity Research
Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.
Mallinckrodt (MNK) Beats on Q2 Earnings and Sales, Ups View
by Zacks Equity Research
Mallinckrodt (MNK) surges following earnings and sales beat in the second quarter. Increase in annual guidance is impressive as well.
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
The FDA accepts Catalyst's (CPRX) NDA for its lead pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and an action date of Nov 28, 2018 is set for the same.
AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.
VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y
by Zacks Equity Research
VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.
Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q2. However, sales of its newest drug, Vyxeos disappoint. Stock down 7% in after-hours trading.
Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.
Medicines Company (MDCO) Q2 Loss Narrows, Revenues Tank Y/Y
by Zacks Equity Research
The Medicines Company (MDCO) beats earnings estimates while missing the same for revenues in the second quarter.
Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track
by Zacks Equity Research
Ophthotech reports narrower-than-expected loss in the second quarter.
Geron (GERN) Q2 Loss In Line, Revenues Up Y/Y, Shares Down
by Zacks Equity Research
Geron (GERN) meets earnings estimates on higher sales in the second quarter. Operating expenses however increase year over year.
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates as well as rides high on revenue beat in Q2.
4 Biotech Bets to Watch as Industry Rebounds in a Month
by Madhu Goel
The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.
Why Is Seattle Genetics (SGEN) Up 13.3% Since Its Last Earnings Report?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seattle Genetics (SGEN) Q1 Earnings Lag Estimates, Sales Top
by Zacks Equity Research
Seattle Genetics (SGEN) first-quarter earnings miss estimates while sales beat the same.